Reimbursement Rejection On Cost Grounds For “Highly Effective” Trodelvy In England
Country Out Of Sync With Other Project Orbis Markets On Gilead Product
Executive Summary
In a draft decision NICE, the health technology appraisal body for England and Wales, has declined to recommend Gilead’s Trodelvy for triple negative breast cancer patients.
You may also be interested in...
Dutch Minister Demands ‘Socially Acceptable’ Price For Gilead’s Trodelvy
Gilead’s breast cancer drug Trodelvy is too expensive for the benefits it offers and will not be reimbursed in the Netherlands unless the company drops its price, said the Dutch health minister.
The Evolution Of Drug Regulation In Post-Brexit Britain
Regulatory reliance is playing an increasingly important role in gaining marketing authorization in the UK following Brexit. Meanwhile, the country’s unique Innovative Licensing and Access Pathway is attracting growing levels of interest, not just from companies but from regulators and health technology appraisal bodies across the world.
New Pricing Deals Pave Way For Piqray & Trodelvy Reimbursement In England
Health technology assessment body NICE has reversed its previous rejections of Novartis’s Piqray and Gilead’s Trodelvy, both for treating advanced breast cancer. Meanwhile, there are calls to speed up reimbursement decisions for breast cancer drugs.